thefirsthalf-2019

First half 2019: High levels of investment in R&D and robust organic growthResearch pipeline further strengthenedNet sales growth rise by currency-adjusted 4.6%; human pharmaceuticals growth driversGroup outlook for 2019 confirmed

Source: Boehringer Ingelheim Corporate News - August 1, 2019 Category: Research Source Type: news